目的 探討保婦康栓聯(lián)合氟羅沙星膠囊治療慢性盆腔炎的臨床療效。方法 選取2022年4月—2023年9月在北京市第六醫(yī)院就診的92例慢性盆腔炎患者，按照隨機(jī)數(shù)字表法將患者分為對(duì)照組和治療組，每組各46例。對(duì)照組口服氟羅沙星膠囊，2粒/次，2次/d。治療組在對(duì)照組基礎(chǔ)上使用保婦康栓治療，外陰部洗凈后將保婦康栓推入陰道深處，1粒/次，每晚1次。7 d為1個(gè)療程，兩組患者共治療2個(gè)療程。比較兩組的治療效果、癥狀緩解時(shí)間、超聲指標(biāo)、血液流變學(xué)和血清指標(biāo)。結(jié)果 治療后，治療組的總有效率為93.48%，對(duì)照組的總有效率為78.26%，組間比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，治療組腰骶疼痛、下腹痛、白帶量多、神疲乏力緩解時(shí)間明顯短于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組的炎性包塊最大直徑、盆腔積液量比治療前?。?i>P＜0.05）；治療組的炎性包塊最大直徑、盆腔積液量比對(duì)照組?。?i>P＜0.05）。治療后，兩組的血漿黏度、血沉、纖維蛋白原比治療前?。?i>P＜0.05）；治療組的血漿黏度、血沉、纖維蛋白原均比對(duì)照組?。?i>P＜0.05）。治療后，兩組的血清白細(xì)胞介素-2（IL-2）水平比治療前升高，血清單核細(xì)胞趨化蛋白-1（MCP-1）、腫瘤壞死因子-α（TNF-α）水平比治療前降低（P＜0.05）；治療組的血清IL-2水平比對(duì)照組高，血清MCP-1、TNF-α水平比對(duì)照組低（P＜0.05）。結(jié)論 保婦康栓聯(lián)合氟羅沙星膠囊可提高慢性盆腔炎的治療效果，縮小炎性包塊，改善血液流變學(xué)水平，減輕炎癥反應(yīng)。

Objective To investigate the clinical effect of Baofukang Suppository combined with Fleroxacin Capsules in treatment of chronic pelvic inflammatory disease. Methods Patients (92 cases) with chronic pelvic inflammatory disease in Beijing Sixth Hospital from April 2022 to September 2023 were divided into control and treatment groups according to the random number method, and each group had 46 cases. Patients in the control group were po administered with Fleroxacin Capsules, 2 grains/time, twice daily. Patients in the treatment group were given with Baofukang Suppository on the basis of the control group, after washing the external genitalia, pushing the Baofukang Suppository deep into the vagina, once daily. One course of treatment had 7 days, and patients in two groups were treated for 2 courses. After treatment, the clinical efficacies, the symptom relief time, ultrasound indicators, hemorheology, and serum indicators in two groups were compared. Results After treatment, the total effective rate of the treatment group was 93.48%, while the total effective rate of the control group was 78.26%, and the difference between the groups was statistically significant (P < 0.05). After treatment, the relief time for lumbosacral pain, lower abdominal pain, excessive vaginal discharge, and fatigue in the treatment group was significantly shorter than that in the control group, and the difference was statistically significant (P< 0.05). After treatment, the maximum diameter of inflammatory masses and pelvic fluid accumulation in two groups were smaller than before treatment (P< 0.05), and the maximum diameter of inflammatory masses and pelvic fluid accumulation in the treatment group were smaller than those in the control group (P < 0.05). After treatment, the plasma viscosity, erythrocyte sedimentation rate, and fibrinogen in two groups were lower than before treatment (P < 0.05), and the plasma viscosity, erythrocyte sedimentation rate, and fibrinogen in the treatment group were all lower than those in the control group (P < 0.05). After treatment, the serum levels of IL-2 were higher than before treatment, but the serum levels of MCP-1 and TNF-α were lower than before treatment (P < 0.05). After treatment, the serum levels of IL-2 in the treatment group was higher than that in the control group, but the serum levels of MCP-1 and TNF-α were lower than those in the control group (P < 0.05). Conclusion Baofukang Suppository combined with Fleroxacin Capsules can further improve the therapeutic effect of chronic pelvic inflammatory disease, further reduce inflammatory mass, improve hemorheology level, and reduce inflammatory response.

R984